Induced sputum in systemic sclerosis: A new potential for biomarkers in SSc P. Jacquerie (Liège, Belgium), B. André (Liège, Belgium), M. Henquet (Liège, Belgium), C. Moermans (Liège, Belgium), D. De Seny (Liège, Belgium), F. Gester (Liège, Belgium), R. Louis (Liège, Belgium), M. Malaise (Liège, Belgium), J. Guiot (Liège, Belgium)
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Disease area: Interstitial lung diseasesRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Jacquerie (Liège, Belgium), B. André (Liège, Belgium), M. Henquet (Liège, Belgium), C. Moermans (Liège, Belgium), D. De Seny (Liège, Belgium), F. Gester (Liège, Belgium), R. Louis (Liège, Belgium), M. Malaise (Liège, Belgium), J. Guiot (Liège, Belgium). Induced sputum in systemic sclerosis: A new potential for biomarkers in SSc. 1369
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Anti-a-enolase antibodies in systemic sclerosis identify a subset of patients with diffuse cutaneous sclerosis and interstitial lung disease Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008
Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis Source: Eur Respir J 2009; 34: 1376-1382 Year: 2009
Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003
Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis Source: Eur Respir J 2011; 38: 1355-1360 Year: 2011
IGFBP-2: a new pathway in systemic sclerosis associated interstitial lung disease Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019
Auto-antibody subsets and extent of pulmonary fibrosis in systemic sclerosis (SSc) Source: Eur Respir J 2005; 26: Suppl. 49, 202s Year: 2005
The genetics of systemic sclerosis Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension Year: 2008
Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020
Interstitial lung disease in systemic sclerosis: where do we stand? Source: Eur Respir Rev 2015; 24: 411-419 Year: 2015
Metabolic profiling of pulmonary vascular phenotypes in systemic sclerosis Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020
Clinical characteristics of interstitial lung fibrosis in progressive systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 95s Year: 2006
The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005
CCL18 as marker of disease progression in systemic sclerosis Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis Year: 2012
Pulmonary hypertension in systemic sclerosis: different phenotypes Source: Eur Respir Rev, 26 (145) 170056; 10.1183/16000617.0056-2017 Year: 2017
Clinical and laboratory features of systemic sclerosis with pulmonary involvement Source: Eur Respir J 2001; 18: Suppl. 33, 512s Year: 2001
Longitudinal functional evaluation of interstitial lung disease in systemic sclerosis Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020
Pulmonary functions in systemic sclerosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012
A systematic review of overlapping microRNA patterns in systemic sclerosis and idiopathic pulmonary fibrosis Source: Eur Respir Rev, 26 (144) 160125; 10.1183/16000617.0125-2016 Year: 2017
Potential new biomarkers for idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020
Systemic lupus erythematosus (SLE): Cyto- and chemokines as possible serum markers for pulmonary involvement? Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012